Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
Patients with familial hypercholesterolemia (FH) have an increased risk of having abnormally high low-density lipoprotein cholesterol (LDL-C) levels. One of the main groups of drugs used for FH is statins....
Conclusions: The data extraction from these studies showed that alirocumab and evolocumab were efficacious in decreasing LDL-C levels and achieving the pre-defined LDL-C goals. Many parameters influenced the strength of the LDL-C reduction: sample size of the population, genetic structure of the patients affected by FH, length of the trial, or...
The prevention of stroke by statins: A meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36197216/
1 School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Jingyue National High-Tech Industrial Development Zone, Changchun, Jilin, China. 2 Department of Encephalology, The Affiliated Hospital of Changchun University...
Conclusions: Our findings indicated that the statins were associated with the patients with stroke in recurrence rate, but there was no significant correlation with the mortality and morbidity of patients with stroke.
Genetic and molecular architecture of familial hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36196022/
Atherosclerotic cardiovascular disease is the first cause of death globally. Despite its important risk of premature atherosclerosis and cardiovascular disease, Familial hypercholesterolemia (FH) is still largely underdiagnosed worldwide. It is...
Conclusions: In the last two decades, major progress has been made in clinical and genetic diagnostic tools and the therapeutic arsenal against FH. Improving prevention, diagnosis and treatment, and making them more accessible to all patients will help reduce the lifelong burden of the disease.
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36193738/
The current evidence from a landscape of preclinical and clinical studies examining the role of PCSK9 in NAFLD shows controversial results. Preclinical studies indicate that PCSK9 associates with NAFLD and...
Expert Opinion: The current evidence from a landscape of preclinical and clinical studies examining the role of PCSK9 in NAFLD shows controversial results. Preclinical studies indicate that PCSK9 associates with NAFLD and nonalcoholic steatohepatitis (NASH) progression in opposite directions. In humans, it has been concluded that the severity of...
Healthcare Access Among Individuals of Asian Descent in the U.S - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36196100/
1 Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, TX. 2 Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH. 3 Division of Medicine, Forrest General Hospital, Hattiesburg,...
Conclusions: Conclusions: Among Asians living in the U.S. with cardiovascular risk factors or ASCVD, Asian Indians and Other Asians are more likely to report delayed care or no care due to cost compared with Chinese.